AntiNarcoleptic Drugs vs Narcolepsy Chronic Sleep disorder.mp4
AntiNarcoleptic drugs vs Narcolepsy chronic sleep disorder.mp4 – Narcolepsy is a chronic neurological disorder caused by the brains inability to regulate the correct times for sleeping and the correct times to be awake. At various moments throughout the day, people with narcolepsy experience sudden urges to sleep. If the urge becomes overwhelming, they may do so for periods lasting from a few seconds to several minutes. The condition is profoundly disabling, interrupting lifes basic day to day activities, including working, driving, even conversing with others. Narcolepsy affects about 1 in every 2000 Americans. Narcolepsy is a chronic sleep disorder, or dyssomnia, characterized by excessive daytime sleepiness (EDS) in which a person experiences extreme fatigue and possibly falls asleep at inappropriate times, such as while at work or at school. Narcoleptics usually experience disturbed nocturnal sleep and an abnormal daytime sleep pattern, which is often confused with insomnia. When a narcoleptic falls asleep they generally experience the REM stage of sleep within 10 minutes; whereas most people do not experience REM sleep until after 90 minutes. There is little evidence to suggest that narcoleptics tend to have a shorter life span. Provigil: An oral drug first approved by the FDA in 1998 for the treatment of narcolepsy, a condition in which there is an uncontrollable desire to sleep. Provigil promotes wakefulness. In 2004 the FDA also approved Provigil for the treatment of obstructive sleep apnea and sleeping problems caused by shift …
Time for Irish patients to benefit from legal cannabis
Filed under: drug addiction treatment act 2000
Preparations of the leaves and resin of the cannabis plant have been in use for over 2,000 years. … Although cannabis is still an illegal substance under the Republic's Misuse of Drugs Act, a derivative, Sativex, has been recommended for approval by …
Read more on Irish Times
Abbott Laboratories – Special Call
Filed under: drug addiction treatment act 2000
This study is a 12-week, interferon-free treatment regimen using ABT-450 ritonavir, ABT-267, ABT-333 and ribavirin, and achieved SVR12 rates observed data of 99% in treatment-naïve patients and 93% in prior null responders with hepatitis C genotype 1 …
Read more on Seeking Alpha